Skip to content

Preferred Stock at other companies

Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$0
Summit Therapeutics logo
Summit TherapeuticsSMMT
$0
Incyte logo
IncyteINCY
$0
Enliven Therapeutics logo
Enliven TherapeuticsELVN
$0
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$0
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$0

Other financials

Income statement

See full
Revenue$71.4M+44.8%
Gross profit$28.9M+338%
Operating income-$81.0M+33.1%
Net income-$79.0M+32.0%
EPS (diluted)-$0.19+47.2%

Balance sheet

See full
Cash & equivalents$196.5M+14.5%
Total debt$46.8M-11.3%
Total equity$721.8M-6.0%
Total assets$925.7M-4.2%

Cash flow

See full
Operating cash flow-$72.1M+30.5%
CapEx$6.6M+6.4%
Free cash flow-$78.7M+28.4%

Valuation

See full
Market cap$1.98B+32.4%
Enterprise value$1.83B+33.2%
P/S6.9×-0.1×

Profitability

See full
Gross margin36.7%+4.1pp
Operating margin-127.2%-31.0pp
Net margin-123.9%-28.4pp
FCF margin-106.8%-27.5pp

Returns & leverage

See full
Return on equity-47.5%-3.7pp
Debt / equity0.1×0.0×
Current ratio3.6×-0.6×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 9, 2016, on SEC EDGAR. View the filing →

Questions, answered.

What does preferred stock mean?
Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.